CHICAGO — Isatuximab combined with a standard first-line treatment regimen significantly reduced the risk for disease progression and death in certain older individuals with multiple myeloma, results from a randomized phase 3 study showed.
Additionally, patients with newly diagnosed, transplant-ineligible disease treated in the isatuximab (Sarclisa, Sanofi) arm of the IMROZ trial had superior PFS and response rates, including minimal residual disease (MRD) complete responses, according to findings presented at ASCO Annual Meeting and simultaneously published in The New England Journal of
